Hydroxyurea (cas 127-07-1): Analytical techniques and quantitative analysis

Add time:09/25/2019    Source:sciencedirect.com

Hydroxyurea is a potent disease-modifying therapeutic agent with efficacy for the treatment of sickle cell anemia. When administered at once-daily oral doses that lead to mild marrow suppression, hydroxyurea leads to substantial and sustained fetal hemoglobin induction, which effectively inhibits erythrocyte sickling. When escalated to maximum tolerated dose, hydroxyurea has proven laboratory and clinical effects for both children and adults with sickle cell anemia. However, there is substantial inter-patient variability with regard to the optimal dosing regimen, as well as differences in treatment-related toxicities and responses that may be explained by hydroxyurea pharmacokinetics and pharmacogenetics. Addressing the safety and efficacy of hydroxyurea treatment requires quantitative and accurate drug analysis, and various laboratory techniques have been established. We review the historical and current analytical techniques for measuring hydroxyurea concentrations accurately, and discuss clinical settings where quantitative analysis can increase understanding and safety of this important therapeutic agent, and ultimately improve patient outcomes.

We also recommend Trading Suppliers and Manufacturers of Hydroxyurea (cas 127-07-1). Pls Click Website Link as below: cas 127-07-1 suppliers

Prev:Hydroxyurea (cas 127-07-1) embryotoxicity is enhanced in P53-deficient mice
Next:p53 mediates Hydroxyurea (cas 127-07-1) resistance in aneuploid cells of colon cancer)